Skip to content

Patient Reported Experiences and Outcomes Associated with Standard C-Section Wound Closure Versus STRATAFIX/DERMABOND PRINEO Wound Closure (CS-PREO)

Patient Reported Experiences and Outcomes Associated with C-Section Wound Closure Bundle

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06614829
Acronym
CS-PREO
Enrollment
68
Registered
2024-09-26
Start date
2024-10-22
Completion date
2025-12-31
Last updated
2024-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section; Complications, Wound, Infection (Following Delivery)

Brief summary

The aim of the study is to compare outcomes between patients receiving standard C-section wound closure compared to a wound closure bundle that includes Stratafix sutures and Dermabond PRINEO.

Detailed description

The purpose of this study is to evaluate patient experience and patient reported outcomes following cesarean delivery in women receiving either standard wound closure or a wound closure bundle which includes both Stratfix sutures and Dermabond Prineo. Patients in both study arms will complete established questionnaires capturing patient-reported experience measures (PREMS) and patient-reported outcome measures (PROMS).

Interventions

Stratafix sutures are barbed and have an antimicrobial coating. The barbs maintain tension during and allows for knotless suturing. The antimicrobial coating inhibits bacterial colonization of the wound.

DERMABOND™ PRINEO™ Skin Closure System is a sterile, liquid topical skin adhesive. It also incorporates a self-adhering mesh that is applied to the approximated skin edges to provide temporary skin edge alignment until the liquid adhesive is applied to achieve skin closure. It forms a strong, flexible, waterproof microbial barrier-as long as the adhesive film remains intact-that falls off naturally after 7-14 days. Dermabond Prineo system will be applied to the skin for skin closure.

Sponsors

Johnson & Johnson
CollaboratorINDUSTRY
North York General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Parallel between group study

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient must be 18 years of age or older at time of recruitment 2. Patients opting for a planned (elective) C-Section (13-36 weeks gestation) will be eligible to consent. 3. Patients must have internet access and/or a smartphone in order to access the digital platform to complete the study questionnaires 4. Patients must speak and write in English as study questionnaires will only be provided in English 5. Patients must have coverage from the Ontario Health Insurance Plan (OHIP)

Exclusion criteria

1. Patients assessed by the participating surgeon with any conditions that may compromise their: * Ability to consent or use the virtual care platform (e.g., patients with intellectual disabilities) * Expectation of significant maternal complications that may affect the surgery 2. Patients who enroll in the study but have an unplanned emergency C-section

Design outcomes

Primary

MeasureTime frameDescription
Diagnosed surgical site infection [Surgical site infection questionnaire completed at follow-up appointment]Assessed at approximately 6 week follow-up appointmentCategories include: no, superficial, deep, organ/space
Canadian Patient Experiences Survey - Inpatient Care + maternity questionsAssessed roughly 48-72 hours after C-section deliveryValidated patient reported experience measure (PREM) assessing 1) communication with nurses, 2) communication with doctors, 3) involvement in decision-making and treatment options, 4) information and understanding when leaving the hospital, and 5) overall hospital experience
SCAR-Q ScoresAssessed at approximately 6 week follow-up appointmentValidated patient reported outcome measure (PROM) assessing three domains: 1) Scar appearance, 2) Scar Symptoms, and 3) Psychosocial Impact
Readmission to any hospital following birth [Surgical site infection questionnaire completed at follow-up appointment]Assessed at approximately 6 week follow-up appointmentSelf-reported by patient
Antibiotic prescription for treatment of infection [Surgical site infection questionnaire completed at follow-up appointment]Assessed at approximately 6 week follow-up appointmentSelf-reported by patient

Countries

Canada

Contacts

Primary ContactMark Fan, MHSc
humanera@nygh.on.ca416-756-6000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026